Veloxis Pharmaceuticals, Inc. v. Glenmark Pharmaceuticals Inc., USA

Case Overview and Background

This patent infringement lawsuit is a classic Hatch-Waxman (ANDA) case, a type of litigation common in the pharmaceutical industry that determines when a generic drug can enter the market. The plaintiff, Veloxis Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on transplant patients and is the U.S. operating arm of the Danish company Veloxis Pharmaceuticals A/S, which is owned by the Japanese conglomerate Asahi Kasei. Veloxis markets Envarsus XR®, a once-daily, extended-release tablet formulation of the immunosuppressant drug tacrolimus, used to prevent organ rejection in kidney transplant patients. The defendant, Glenmark Pharmaceuticals Inc., USA, is the U.S. subsidiary of the India-based global pharmaceutical company Glenmark Pharmaceuticals Ltd. Glenmark is a major manufacturer of generic drugs and has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Envarsus XR.

The filing of Glenmark's ANDA is the act of infringement that triggered this lawsuit. Under the Hatch-Waxman Act, a generic drug company's application to the FDA that challenges the patents listed for a branded drug is considered a technical act of patent infringement, allowing the brand manufacturer to sue before the generic product actually launches. Veloxis alleges that Glenmark's proposed generic product will infringe U.S. Patent No. 12,403,095, which is listed in the FDA's "Orange Book" as covering Envarsus XR. While the specific text of this very recent patent is not yet widely available in public search results, related Veloxis patents for Envarsus XR describe an extended-release oral dosage form of tacrolimus for once-daily immunosuppressive treatment. This technology, which Veloxis calls MeltDose®, is designed to improve the absorption and provide stable, 24-hour blood levels of the active drug, tacrolimus.

The case is filed in the U.S. District Court for the District of Delaware, a premier venue for patent litigation, particularly for pharmaceutical ANDA cases. Due to the large number of U.S. corporations incorporated in Delaware, it is a proper venue for many patent defendants, and its judiciary is highly experienced in handling these complex, high-stakes cases. This litigation is significant as it directly impacts when a lower-cost generic alternative to Envarsus XR can become available to patients. For Veloxis, a victory would protect a key revenue stream, while for Glenmark, a successful challenge could grant it 180 days of market exclusivity as the first-to-file generic, a period that can be extremely profitable. The outcome will determine market competition for this important anti-rejection medication.

Key Legal Developments and Case Posture

As of May 7, 2026, the patent infringement litigation between Veloxis Pharmaceuticals and Glenmark Pharmaceuticals is in its very early stages. Key developments have been limited to the initial filings that formally commenced the lawsuit.

Chronology of Developments:

• 2026-02-07: Veloxis received Glenmark's Paragraph IV notice letter, the formal notification required under the Hatch-Waxman Act, advising that Glenmark had filed an Abbreviated New Drug Application (ANDA) seeking FDA approval to market a generic version of Envarsus XR before the expiration of U.S. Patent No. 12,403,095. This notice triggered the 45-day window for Veloxis to file a patent infringement lawsuit to secure an automatic 30-month stay of FDA approval for Glenmark's ANDA.

• 2026-03-20: Veloxis filed its Complaint for patent infringement against Glenmark in the U.S. District Court for the District of Delaware. The complaint (D.I. 1) alleges that Glenmark's submission of its ANDA constitutes an act of infringement under 35 U.S.C. § 271(e)(2). On the same day, Veloxis also filed a corporate disclosure statement identifying Asahi Kasei Corp. as its parent company and other required procedural documents.

• 2026-03-23: A summons was issued to Glenmark, and the docket confirms that Glenmark was formally served on this date. Under federal rules, Glenmark's answer to the complaint was initially due by April 13, 2026.

Current Status and Next Steps:

The case is currently in the initial pleadings stage. The docket does not yet show that Glenmark has filed its Answer or any counterclaims. It is common for defendants in such cases to request an extension of time to respond to the complaint. Once Glenmark files its Answer, it is expected to deny infringement and assert that Veloxis's patent is invalid and/or unenforceable.

Following the pleading stage, the court will likely issue a scheduling order setting deadlines for key milestones, including:

• Discovery
• Claim construction (Markman) briefing and hearing
• Dispositive motion deadlines (e.g., summary judgment)
• Pre-trial conference and trial dates

Under the Hatch-Waxman framework, the filing of this lawsuit automatically triggers a 30-month stay on the FDA's ability to grant final approval to Glenmark's ANDA. This stay is currently set to expire around September 2028, creating a critical timeline for the resolution of this litigation.

Parallel PTAB Proceedings:

A search of the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) records does not currently show any inter partes review (IPR) or post-grant review (PGR) petitions filed by Glenmark challenging the validity of U.S. Patent No. 12,403,095. It is a common strategy for ANDA defendants to file IPR petitions concurrently with district court litigation, as the PTAB can be a faster and sometimes more favorable venue for invalidating patents. It is possible that Glenmark will file such a petition in the coming months, which could lead to a motion to stay the district court case pending the PTAB's decision.

As of the current date, attorneys from Morris, Nichols, Arsht & Tunnell LLP have appeared on behalf of the plaintiff, Veloxis Pharmaceuticals, Inc. The case is in its early stages, and additional counsel may be added as the litigation progresses.

Based on initial filings and counsel's history in similar cases, the legal team for Veloxis includes the following:

Plaintiff's Counsel of Record

• Name: Jeremy A. Tigan

  • Role: Likely Lead Counsel / Filing Counsel
  • Firm: Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)
  • Noteworthy Experience: Mr. Tigan is a partner in the firm's Intellectual Property Litigation Group and has extensive experience representing major pharmaceutical companies in Hatch-Waxman (ANDA) litigation in the District of Delaware. He is listed on the docket as the representing attorney for Veloxis. He also represented Veloxis in a prior ANDA case filed in 2025 against the same defendant, Glenmark.

• Name: Unspecified partners and associates

  • Role: Co-counsel
  • Firm: Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)
  • Note: While only Mr. Tigan is explicitly named on the initial docket summary available through public search, it is standard practice in ANDA litigation for a team of attorneys to be involved. Morris, Nichols, Arsht & Tunnell LLP is a prominent Delaware firm frequently retained by brand-name pharmaceutical companies for patent litigation. In a 2022 ANDA case, Veloxis was represented by the firm, indicating an established relationship.

• Name: Noel Barnard

  • Role: In-House Counsel
  • Firm: Veloxis Pharmaceuticals, Inc.
  • Noteworthy Experience: As Vice President, Legal and General Counsel for Veloxis since 2018, Ms. Barnard is responsible for overseeing all of the company's global legal affairs, including its intellectual property portfolio and litigation strategy. While she will not likely appear directly on court filings, she manages the outside litigation team.

Note: The public docket information is still developing for this recent case. The full legal team for Veloxis will become clearer as additional attorneys file notices of appearance.

Counsel of Record for Defendant Glenmark Pharmaceuticals Inc., USA

As of May 7, 2026, counsel for the defendant, Glenmark Pharmaceuticals Inc., USA, has not yet formally entered an appearance on the docket for case number 1:26-cv-00305 in the U.S. District Court for the District of Delaware.

Under the Federal Rules of Civil Procedure, a defendant typically has 21 days to respond to a complaint after being served. Given the case was filed on March 20, 2026, and allowing for time for service of process, an appearance or responsive pleading is expected shortly. It is common in ANDA litigation for defense counsel to be retained quickly, but their formal notice of appearance may not be the first document filed.

While no attorneys are officially on record for Glenmark in this specific matter, analysis of Glenmark's litigation history in similar ANDA cases often shows representation by law firms with deep expertise in pharmaceutical patent litigation. Based on past retentions, it is plausible that counsel from firms specializing in this area will appear. However, until a notice of appearance is filed on the public docket, any specific names would be speculation. Filings in the coming weeks should clarify Glenmark's legal representation in this case.